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Abstract
Background: Acne vulgaris is a common skin disease that affects not only teenagers but also the general
population. Although acne is not physically disabling, its psychological impact can be striking, contributing to
low self-esteem, depression, and anxiety. As a result, there is a significant demand for effective acne therapies.
Antihistamine is a widely used medication to treat several allergic skin conditions and yet it also has been
found to decrease complications of acne and improve acne symptoms. For the severe cystic acne vulgaris, oral
retinoids such as isotretinoin is the primary treatment; however, health care providers hesitate to prescribe
isotretinoin due to its adverse drug reactions. On the other hand, antihistamine is well known by its safe and
minimal side effects. Can an antihistamine intervention in standardized treatment of acne vulgaris
significantly impact the improvement of acne symptoms and reduce sebum production?
Methods: An exhaustive search was conducted by MEDLINE-OVID, CINAHL, UptoDate, Web of Science,
Google scholar, MEDLINE-PubMed, Clinicalkey, and ProQuest by using keywords: acne vulgaris and
antihistamine. Relevant articles were assessed for quality using GRADE.
Results: After the exhaustive search, two studies met the inclusion criteria and eligibility criteria. Effect of
antihistamine as an adjuvant treatment of isotretinoin in acne:a randomized, controlled comparative study contains
the comparison of 20 patients with moderate acne are treated with isotretinoin and another 20 patients with
moderate acne are treated with additional antihistamine. Identification of Histamine Receptors and Reduction of
Squalene Levels by an Antihistamine in Sebocytes was conducted on human tissue to verify the decrease of
sebum production by the antihistamine’s effect.
Conclusion: Both studies demonstrate the usefulness of an histamine antagonist in reducing sebum
production and improving acne symptoms. Due to its low cost and safety, a recommendation can be made for
antihistamine to treat acne vulgaris as an adjuvant therapy to standardized treatment.
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Abstract   
Background: Acne vulgaris is a common skin disease that affects not only teenagers but 
also the general population. Although acne is not physically disabling, its psychological 
impact can be striking, contributing to low self-esteem, depression, and anxiety. As a 
result, there is a significant demand for effective acne therapies. Antihistamine is a 
widely used medication to treat several allergic skin conditions and yet it also has been 
found to decrease complications of acne and improve acne symptoms. For the severe 
cystic acne vulgaris, oral retinoids such as isotretinoin is the primary treatment; however, 
health care providers hesitate to prescribe isotretinoin due to its adverse drug reactions. 
On the other hand, antihistamine is well known by its safe and minimal side effects. Can 
an antihistamine intervention in standardized treatment of acne vulgaris significantly 
impact the improvement of acne symptoms and reduce sebum production? 
 
Methods:  An exhaustive search was conducted by MEDLINE-OVID, CINAHL, 
UptoDate, Web of Science, Google scholar, MEDLINE-PubMed, Clinicalkey, and 
ProQuest by using keywords: acne vulgaris and antihistamine. Relevant articles were 
assessed for quality using GRADE.   
 
Results:  After the exhaustive search, two studies met the inclusion criteria and eligibility 
criteria. Effect of antihistamine as an adjuvant treatment of isotretinoin in acne:a 
randomized, controlled comparative study contains the comparison of 20 patients with 
moderate acne are treated with isotretinoin and another 20 patients with moderate acne 
are treated with additional antihistamine. Identification of Histamine Receptors and 
Reduction of Squalene Levels by an Antihistamine in Sebocytes was conducted on human 
tissue to verify the decrease of sebum production by the antihistamine’s effect. 
 
Conclusion: Both studies demonstrate the usefulness of an histamine antagonist in 
reducing sebum production and improving acne symptoms. Due to its low cost and 
safety, a recommendation can be made for antihistamine to treat acne vulgaris as an 
adjuvant therapy to standardized treatment. 
 
Keywords:  Acne vulgaris, antihistamine 
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Antihistamine: A Useful Medication with Minimal Adverse Drug 
Reactions to Improve Acne Symptoms and Reduce Sebum Production 
BACKGROUND  
 Acne Vulgaris is one of the most common cutaneous disorders worldwide 
affecting any age or race group. The reported prevalence of acne varies from 35% to over 
90% of adolescents at some stage; moreover, a significant number of patients continue to 
experience acne or develop new-onset acne after the teenaged years.1,2 There are 
abundant resources mentioning antihistamine treatment as adjuvant therapy to resolve 
complications of acne vulgaris such as itchiness, urticaria and edema, and some resources 
even mention its effectiveness in reducing inflammation and preventing scar formation. 
Although acne is not physically disabling, its psychological impact can be striking, 
contributing to low self-esteem, depression, and anxiety.3-5 As a result, there is a 
significant demand for effective acne therapies. Current treatment of acne vulgaris 
includes topical and oral antibiotics, hormonal therapy, antiseptic medication and 
retinoids.6  
For the severe cystic ance vulgaris, oral retinoids such as isotretinoin are 
considered the most effective treatment7, 8; however, health care providers hesitate to 
prescribe isotretinoin due to its adverse drug reactions.9, 10 On the other hand, 
antihistamine is well known by its safety and minimal side effects. During an immune 
reaction, the inflammatory mediator, histamine, is release into the local environment by 
mast cell and basophils.11 Immunologic reaction to Propionibacterium acne, the causative 
organism of acne vulgaris, and subsequent histamine-mediated inflammatory damage to 
keratinocytes has been discovered.12 In addition, mast cell induced fibrosis in skin and 
elsewhere in the body can complicate acneic lesions by scar formation and can be 
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prevented by antihistamines if administered in time.13, 14  Possible presence of 
dermographism such as subclinical urticarial and facial edema in a large number of acne 
patients could be successfully controlled by provision of antihistamines due to its effect 
on allergic reactions.15  With the role that histamine and sebum production may [;ay in 
acne pathophysiology, can antihistamine treatment be useful in the management of acne 
vulgaris? 
METHODS 
 An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, UptoDate, and Web of Science, Google scholar, MEDLINE-
PubMed, Clinicalkey, and ProQuest by using keywords: acne vulgaris and antihistamine. 
The studies are selected if they were published in the English language, conducted on 
humans or human tissues, published during 2008 or later. They also needed to include a 
comparison of treatment with and without antihistamines to see if antihistamines reduce 
sebum production on human tissue and improves acne symptoms clinically. 
Bibliographies and relevant articles were further researched for sources. Relevant articles 
were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) 16.  
RESULTS 
After the exhaustive search, the initial result yielded 18 articles for review of 
relevancy. Two studies met the eligibility criteria including one randomized controlled 
 - 9 - 
trial17 and one prospective observational study.18The two studies are included in the 
system review. See Table 1. 
Lee et al 
The randomized controlled trial16 sought after the effects of antihistamine as an 
adjuvant treatment of isotretinoin in acne including non-inflammatory lesion count, 
inflammatory lesion count, total lesion count, GAGS score and patient satisfaction. 
Furthermore, sebum excretion and erythema index were measured along the clinical trial. 
Acne flare and side effects are also included as a result. It was designed as a 12-week 
study with blinded assessment of data collectors and three independent dermatologists. 
Forty Korean patients with moderate to severe acne symptoms were enrolled and divided 
evenly into two groups (see Table 2). The control group was treated with isotretinoin 
only (20 mg per day, approximately 0.2–0.4 mg/kg per day); and the treatment group was 
treated with combination therapy of isotretinoin and antihistamine, desloratadine (5 mg 
per day). No other acne treatments besides a washing and moisturizing procedure were 
allowed. Patients with other systemic diseases, concurrent use of other acne therapies, 
other dermatological conditions requiring interfering treatment were excluded as subjects. 
Women who were pregnant, nursing, or planning a pregnancy were excluded due to 
possible hormonal influences. The patients were assessed at the beginning of treatment 
and at 2, 4, 8 and 12 weeks after treatment. T-test and P value were assessed for 
significant differences between two groups at each visit as statistical analysis.17 
The primary outcome was clinical acne symptoms improvement including acne 
lesion counts, severity by GAGS score, and patient satisfaction. Non-inflammatory lesion 
counts and inflammatory lesion counts started to show a significant difference at week 2 
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(P<0.05) and the mean non-inflammatory lesion counts in the treatment group reduced to 
17.8% whereas there is a remaining of 44.8% lesion counts in the control group. 
Correspondingly, inflammatory lesion counts indicate a reduction of 22.9% in the 
treatment group and 55.8% in the control group; likewise, a significant difference of total 
lesion counts was also demonstrated in the 12 weeks of treatment (P<0.001 at week 12). 
According to GAGS score, statistically significant differences were found starting at 
week 4 between the two groups (P<0.05), and it is consistent in percentage with reduction 
of lesion counts from baseline. There were 50% of patients that improved on GAGS 
score and no patients worsened in the treatment group; conversely, 40% of patients 
improved on GAGS score and 10% of patients worsened in the control group comparing 
to the baseline. Patient satisfactions showed a mean ± standard deviation score of 2.75 
±0.18 in control group and 3.4 ±0.15 in treated group on a 4-point scale.17 
Secondary outcomes included skin sebum excretion, erythema measurement, acne 
flare, and side effects. Both sebum excretion (µg/cm2 ) and erythema score (arbitrary 
unit) declined in the control group and the treatment group; however, a statistical 
significant difference was found between the two groups started from week 4 in the case 
of sebum excretion while the significant difference between the two groups started from 
week 2 in the case of erythema scores. In the speaking of acne flares, six patients in the 
control group were evident whereas only one patient in the treatment group experience 
acne flare during the 12-week treatment. Common side effects in both groups include 
cheilitis, xerosis, itchiness, sting, and burning sensation etc. Although both groups 
tolerated treatment generally well, the treatment group showed even better tolerability 
with minimal side effects.17 
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The authors stated the main limitation of the study is that follow-up evaluation 
was not performed after the 12-week clinical trial; therefore, studies with larger sample 
size and longer follow-up period are needed to support the new treatment approach. In 
addition, the authors recommended further studies evaluating the efficacy of 
antihistamines as a single therapeutic method as well as a maintenance therapy after 
achieving remission of disease using isotretinoin.  
Pelle et al 
In this observational study, 18 the authors wanted to identifying histamine 
receptors and reduction of squalene levels by an antihistamine in human sebocytes to 
further extend in acne treatment. Sebocytes are the major cells of the sebaceous gland and 
are responsible for producing sebum. Reducing sebum production minimizes the 
blockage of pores to curtail during an episode of acne growth. The cell cultures were 
obtained as SZ95 sebocytes, an immortalized sebocyte cell line, from Dr. C Zouboulis in 
frozen ampoules. Total RNA was isolated from sebocytes using a High Pure RNA 
Isolation Kit to extract RNA from sebocytes by reverse-transcriptase-polymerase chain 
reaction (RT-PCR) analysis. Immunofluorecence technique was then used to dye and 
verify the existence of histamine receptors in sebocytes and sebaceous gland. The authors 
also extract squalene as a biomarker, which is a major component of human sebocytes, 
from sebocytes to measure its response to 50µM diphenhydramine (DPH) and 100µM 
diphenhydramine. In addition, an experiment was designed to determine the reduction of 
squalene level was not a cytotoxic event caused by diphenhydramine. 18 
Primary outcomes include the presence of histamine receptor in human sebocytes, 
DPH reduces squalene level in sebocyte and proof for the fact that DPH is not cytotoxic. 
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H-1 histamine receptors were clearly identified on RNA extracted from SZ95 sebocytes 
by agarose gel electrophoresis RT-PCR analysis. H-2 receptors were either not detected 
or only slightly discovered during the experiment. They assigned 1× 106 cells each in the 
control group and two experiment groups with 50µm DPH and 100µm DPH. Squalene 
standards were used to calculate the amount of squalene in the samples (nmol): 6.27 
±0.73 SD in control group; 2.37 ±0.24 SD in 50µm DPH group; 2.03 ±0.97 SD in 100µm 
DPH group. (n=4, P<0.08 in 50µm DPH; P<0.03 in 100µm DPH group, using a two-
tailed, Student’s t-test assuming unequal variances). There was no significant cell 
decrease between the control group and the experiment groups when testing on the 
cytotoxicity of DPH after approximately a 16 hour-exposure revealed its non-
cytotoxicity. 18 
There were no limitations stated by the authors; however, they strongly 
encouraged measurements of cAMP levels in sebocytes treated with DPH to be the 
important next step in elucidating the mechanism.    
DISCUSSION 
The prescription of H-1 antagonist is helpful in reducing sebum production due to 
histamine receptors found on human sebocytes and decreased squalene level by using 
DPH, a commonly used H-1 antagonist worldwide.18 In addition, clinical improvement 
on both the GAGS score and patient satisfaction demonstrate antihistamine should be 
included as adjuvant medication in standardized treatment of acne vulgaris.17 Health care 
providers should be encouraged to prescribe antihistamine to the general population 
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affected by acne vulgaris, especially since antihistamines like diphenhydramine have an 
established safety profile. 
The systematic review was able to discuss the two studies17, 18 that provides 
evidence and supports the usefulness of antihistamine in treating acne patients; 
nevertheless, both studies have limitations.  
In Lee et al, 17sample size of a total 40 patients was legitimate yet relatively small. 
Although the process of selecting patients was not explained, it stated it is a randomized, 
controlled comparative study. The authors stated the blinding process included group 
assignment to examiners and blinding three different dermatologists as data collectors 
when assessing each visit of the 40 patients; however, it was not possible to blind the 
patients and providers that prescribed isotretinoin and desloratadine. All the 40 patients 
were assessed at the beginning of the clinical trial using GAGS score and revealed there 
was no significant difference in the control and the treatment group at baseline. At each 
visit of week 2, 4, 8 and 12, GAGS score was again measured and it was consistent to 
acne lesions count. There was no withdrawal in this study; therefore, the attrition bias 
was avoided. The study was the very first randomized controlled clinical trial, and being 
published in Dec. 2014, it is the most current study available on the topic. A larger 
sample size with longer period of following up and relapsing of acne vulgaris after 
treatment could further extended to support this new treatment approach. If antihistamine 
is useful in reducing sebum production and improving the symptoms of acne vulgaris, 
clinicians may be able to try an antihistamine, which may lower the number of patients 
who would need more aggressive treatment such as isotretinoin. In fact the use of 
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antihistamines may even reduce the dosage of isotretinoin to minimize its side effect. 
Moreover, antihistamine could be the treatment of choice as maintenance therapy. This 
could be a new clinical question requiring further research. 
The manner in which the Pelle et al study18 was conducted on human tissue in a 
histological manner without clinical proof on actual acne patients would be an important 
limitation to consider. Furthermore, all cells obtained in the experiment are from one 
female doctor, which led to selection bias as another limitation. There was no blinding 
level mentioned since it is an observational study; otherwise, the results were consistent 
with other aspects of the study. Squalene was used as a biomarker to measure sebum 
production in human sebocytes; however, it is not considered surrogate outcome since it 
is the major component of sebum, and reducing sebum production is an important clinical 
question regarding acne vulgaris. It is strongly suggested by the authors that further 
studies should be conducted on the mechanism of antihistamine reducing sebum 
production. In addition, to explore different types of histamine receptors and 
antihistamine in more detail would be even better to direct health care providers on 
prescribing medications for acne patients. 
There was one clinical study19 worth mentioning which was conducted in 1979. 
The study measured sebum excretion rate on forehead skin before and at intervals during 
l-6 weeks of treatment with cimetidine, an H-2 histamine antagonist, (1 g/day in divided 
doses) in four male and six female patients with acne. The decrease of sebum excretion 
was statistically significant started at week 2 and was still apparent at 5 weeks. Due to the 
lack of control group, the comparison was made between patients before antihistamine 
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treatment and completion of 6 weeks treatment of cimetidine. However, H-2 histamine 
receptors were not commonly found on human sebocytes according to Pelle et al18; 
moreover, the authors of this study stated that they were not sure whether the effect of 
reducing sebum production came from the blockage of histamine receptors or 
antiandrogenic effect of cimetidine itself. This past study and the more recent studies 
show the variety of research that has been and still needs to be done to understand how 
antihistamine relates to acne. 
Acne vulgaris is a broad category that concludes different types of acne 
presentation. Moreover, antihistamine is also a broad category concludes all histamine 
receptors antagonist. Although further studies need to be conducted to direct health care 
providers on prescribing antihistamine, the two studies including in this systematic 
review recommend that health care providers embrace H-1 antihistamine as part of 
standardized treatment for acne patients. It is the new treatment approach in which 
benefits outweigh harms compared to use isotretinoin alone for moderate to severe acne 
symptoms. 
CONCLUSION  
 Antihistamines have demonstrated its usefulness in managing acne vulgaris and it 
should be added as adjuvant treatment on treating acne patients. Despite the severity of 
acne vulgaris, antihistamine will be useful on sebum secretion and its minimal side 
effects are most likely tolerable in all kinds of patients. There may be benefits of 
prescribing antihistamines to patients which need to be evaluated: first reducing or 
avoiding isotretinoin in order to minimize adverse drug reactions, secondly antihistamine 
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has effects on preventing subclinical itching, urticarial, and facial edema, and third its 
anti-inflammatory effect could possibly lower the chances of scar forming and improve 
clinical redness and other symptoms. Moreover, the cost of antihistamine is affordable 
and accepted by the general population. As a result, a recommendation can be made to 
health care providers in adding antihistamine as part of standardized treatment in acne 
patients, even though further randomized controlled studies designed to evaluate the 
effect on clinical improvement are needed. 
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Table 1. GRADE Quality of Assessment 
 
 
a Small sample size  
b Only one study measuring this outcome 
c Pelle et al contains all cells only from one female doctor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment  Importance 
 Downgrade Criteria 
Quality  
No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Clinical Improvement of Acne Symptoms   
1 
 
1 RCT 
 
 No serious 
limitation 
No serious 
indirectness 
Very serious 
imprecisiona, b 
No serious 
inconsistencies No bias likely  Low Critical 
Reduction of Sebum Production   
2 1RCT 1 Observational 
Serious 
limitationc 
No serious 
indirectness 
Very serious 
imprecisiona 
No serious 
inconsistencies No bias likely Very Low 
Important 
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Summary of Findings 
 
Table 2. Lee et al  
Baseline demographic and clinical characteristics of acne patients 
 Isotretinoin (Control) Isotrtinoin +Desloratadine (Treatment) 
Female 12 12 
Male 8 8 
Age (years, mean±SD) 21.9±2.1 21±3.7 
Duration (years, mean±SD) 4.8±2.76 4.6±2.99 
Dosage of isotretinoin (mg/kg 
per day, mean±SD) 0.31±0.05 0.29±0.03 
Non-inflammatory 43.6±19.4 41.5±17.7 
Inflammatory 30±15.5 30.6±17 
Total 73.7±27.7 72±14.9 
GAGS (score, mean±SD) 27.2±6.09 28.2±6.48 
 
Table 3. Lee et al 
Changes in assessment with time and difference between both groups 
Acne lesions Control Treatment Significant 
difference  Baseline Week 12 Baseline Week 12 
Non-inflammtory 100% 44.8% 100% 12.8% P<0.001 
Inflammatory 100% 55.8% 100% 22.9% P<0.001 
GAGS  P<0.05 
Patient 
Satisfaction 
Slightly 
satisfied Satisfied 
Very 
satisfied 
Slightly 
satisfied Satisfied 
Very 
satisfied  Number of 
Patients 9 (45%) 7 (35%) 4 (20%) 2 (10%) 8 (40%) 
10 
(50%) 
Mean±SD  
(4-point scale) 2.75±0.18 3.4±0.15 P<0.05 
Sebum 
Production Significant difference started at Week 4 (P=0.005) P<0.05 
Erythema 
Index Significant difference started at Week 2 (P=0.02) P<0.05 
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Table 4. Pelle et al 
DPH reduces squalene in sebocytes 
 Control 50µM DPH 100µM DPH Significant difference 
Number of cells 1× 106 cells 1× 106 cells 1× 106 cells  
Squalene Level that 
represent Sebum 
Production  
(nmol, mean±SD )  
6.27±0.73 2.37±0.24 2.03±0.97 
P<0.08 in 
50µM DPH 
P<0.03 
in100µM DPH 
 
 
 
 
 
 
 
 
 
 
 
 
 
